ES2091031T3 - Uso de acido hialuronico para prevenir la reestenosis arterial. - Google Patents

Uso de acido hialuronico para prevenir la reestenosis arterial.

Info

Publication number
ES2091031T3
ES2091031T3 ES93920624T ES93920624T ES2091031T3 ES 2091031 T3 ES2091031 T3 ES 2091031T3 ES 93920624 T ES93920624 T ES 93920624T ES 93920624 T ES93920624 T ES 93920624T ES 2091031 T3 ES2091031 T3 ES 2091031T3
Authority
ES
Spain
Prior art keywords
hyaluronic acid
arterial restenosis
prevent arterial
tubular walls
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920624T
Other languages
English (en)
Inventor
Rudolf Edgar Falk
Samuel Simon Asculai
Eva Anne Turley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyal Pharmaceutical Corp
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Application granted granted Critical
Publication of ES2091031T3 publication Critical patent/ES2091031T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

PARA PREVENCION DEL ESTRECHAMIENTO DE LAS PAREDES TUBULARES DE UN ANIMAL TRAS EL TRAUMATISMO DE LAS PAREDES TUBULARES, SE DESCRIBE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA Y NO-TOXICA DE ACIDO HIALURONICO Y/O SUS SALES Y/O HOMOLOGOS, ANALOGOS, DERIVADOS, COMPLEJOS, ESTERES, FRAGMENTOS Y SUBUNIDADES DE ACIDO HIALURONICO AL ANIMAL PARA PREVENIR EL ESTRECHAMIENTO DE LAS PAREDES TUBULARES.
ES93920624T 1992-09-25 1993-09-22 Uso de acido hialuronico para prevenir la reestenosis arterial. Expired - Lifetime ES2091031T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002079205A CA2079205C (en) 1992-09-25 1992-09-25 Use of hyaluronic acid and forms to prevent arterial restenosis

Publications (1)

Publication Number Publication Date
ES2091031T3 true ES2091031T3 (es) 1996-10-16

Family

ID=4150463

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920624T Expired - Lifetime ES2091031T3 (es) 1992-09-25 1993-09-22 Uso de acido hialuronico para prevenir la reestenosis arterial.

Country Status (26)

Country Link
EP (1) EP0661981B1 (es)
JP (1) JP3742955B2 (es)
CN (1) CN1057908C (es)
AP (1) AP448A (es)
AT (1) ATE141054T1 (es)
AU (1) AU670117B2 (es)
BR (1) BR9307221A (es)
CA (1) CA2079205C (es)
CZ (1) CZ288986B6 (es)
DE (1) DE69303931T2 (es)
DK (1) DK0661981T3 (es)
ES (1) ES2091031T3 (es)
GR (1) GR3021171T3 (es)
HK (1) HK35397A (es)
HU (2) HU227067B1 (es)
IL (1) IL107087A0 (es)
IN (1) IN181289B (es)
MD (1) MD960294A (es)
MX (1) MX9305887A (es)
NO (1) NO309457B1 (es)
NZ (1) NZ255978A (es)
PL (1) PL308201A1 (es)
SG (1) SG48845A1 (es)
SK (1) SK36895A3 (es)
TW (1) TW271401B (es)
ZA (1) ZA937068B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2301018C (en) * 1997-08-22 2006-06-20 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid gel, method of its production and medical material containing it
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease

Also Published As

Publication number Publication date
AP448A (en) 1996-01-18
HUT73637A (en) 1996-08-28
CZ66295A3 (en) 1996-02-14
HU9500857D0 (en) 1995-05-29
NO309457B1 (no) 2001-02-05
CA2079205C (en) 1998-02-10
HU227067B1 (en) 2010-06-28
AU670117B2 (en) 1996-07-04
GR3021171T3 (en) 1996-12-31
HU211698A9 (en) 1995-12-28
EP0661981A1 (en) 1995-07-12
NZ255978A (en) 1997-02-24
DE69303931D1 (de) 1996-09-12
IN181289B (es) 1998-05-02
MD960294A (ro) 1997-10-31
PL308201A1 (en) 1995-07-24
CA2079205A1 (en) 1994-03-26
EP0661981B1 (en) 1996-08-07
MX9305887A (es) 1994-05-31
ATE141054T1 (de) 1996-08-15
SK36895A3 (en) 1997-03-05
TW271401B (es) 1996-03-01
NO951122D0 (no) 1995-03-23
SG48845A1 (en) 1998-05-18
AU4812693A (en) 1994-04-26
DE69303931T2 (de) 1997-01-09
ZA937068B (en) 1994-04-18
CN1057908C (zh) 2000-11-01
HK35397A (en) 1997-03-27
JP3742955B2 (ja) 2006-02-08
IL107087A0 (en) 1993-12-28
DK0661981T3 (da) 1996-12-23
BR9307221A (pt) 1999-07-27
AP9300568A0 (en) 1993-10-31
CZ288986B6 (cs) 2001-10-17
JPH08506797A (ja) 1996-07-23
CN1092654A (zh) 1994-09-28
NO951122L (no) 1995-03-23

Similar Documents

Publication Publication Date Title
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
ES2171543T3 (es) Composiciones administrables topicamente que contienen derivados del acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
ES2155473T3 (es) Composicion veterinaria que contiene un inhibidor de las bombas de protones.
ES2093979T3 (es) Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino)fenilacetico y su procedimiento de preparacion.
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
AR022023A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
ES2126094T3 (es) Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma.
CO4700287A1 (es) Metodo para el tratamiento topico de enfermedades fungales de las unas
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
DK0873351T3 (da) Steroidnitrit/nitratesterderivater anvendelige som antiinflammatoriske lægemidler
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
ES2176468T3 (es) Uso de acido hialuronico y un nsaid para la fabricacion de un medicamento para el tratamiento de enfermedades de las mucosas.
ES2171590T3 (es) Composicion farmaceutica para el tratamiento de rinitis agudas, que contiene un simpatomimetico y pantotenol y/o acido pantotenico.
ES2091031T3 (es) Uso de acido hialuronico para prevenir la reestenosis arterial.
DK0912185T3 (da) Nye farmaceutiske sammensætninger indeholdende steroidnitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
ES2150705T3 (es) Derivados de ester de nitrito esteroideos utiles como farmacos antiinflamatorios.
ATE198477T1 (de) Benzothiophenderivate
ES2145360T3 (es) Sales cristalinas y estables de acido tetrahidrofolico.
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
SE8002322L (sv) Medel for behandling av inflammatoriska tarmsjukdomar
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 661981

Country of ref document: ES

FG2A Definitive protection

Ref document number: 661981

Country of ref document: ES